← Back to Search

Anti-tumor antibiotic

Mitoxantrone + G-CSF for Prostate Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Hope Cancer Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cardiovascular: Must have adequate cardiac function (LVEF at least 40%)
No other malignancy except skin lesions that have been completely excised
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying giving mitoxantrone together with G-CSF to see how well it works in treating patients with metastatic prostate cancer.

Who is the study for?
This trial is for men with metastatic prostate cancer that hasn't improved with hormone therapy. They should have a life expectancy over 12 weeks, good heart and kidney function, no prior chemotherapy or extensive radiation, and no other cancers except certain skin lesions.Check my eligibility
What is being tested?
The study is testing the combination of mitoxantrone (a chemotherapy drug) and G-CSF (a growth factor to boost white blood cells) to see if it can better kill tumor cells in patients whose prostate cancer has spread and isn't responding to hormones.See study design
What are the potential side effects?
Mitoxantrone may cause side effects like nausea, low blood cell counts increasing infection risk, hair loss, mouth sores; G-CSF can cause bone pain, feverish feelings but usually helps reduce infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart's pumping ability is at least 40%.
Select...
I have no cancer other than fully removed skin lesions.
Select...
My prostate cancer is advanced, has spread, and does not respond to hormone therapy.
Select...
My liver function tests are within normal limits.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Select...
My creatinine level is below 1.5 mg/dL.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Hope Cancer Institute, Inc.Lead Sponsor
3 Previous Clinical Trials
113 Total Patients Enrolled
Raj Sadasivan, MD, PhDStudy ChairHope Cancer Institute, Inc.
3 Previous Clinical Trials
113 Total Patients Enrolled

Media Library

Mitoxantrone (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT00003183 — Phase 1 & 2
Prostate Cancer Research Study Groups:
Prostate Cancer Clinical Trial 2023: Mitoxantrone Highlights & Side Effects. Trial Name: NCT00003183 — Phase 1 & 2
Mitoxantrone (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003183 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research still taking on participants?

"According to information posted on clinicaltrials.gov, this trial has concluded its recruitment process and is no longer seeking participants. Initially published on March 1st 1997, the study had last been updated over six years ago in December 2013. Nonetheless, there are currently 1321 other trials searching for patients at this moment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
1997. "Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003183.
All > Prostate > Ic
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top